Correlation Between HLA Alleles and EGFR Mutation in Japanese Patients with Adenocarcinoma of the Lung  by Uramoto, Hidetaka et al.
ORIGINAL ARTICLE
Correlation Between HLA Alleles and EGFR Mutation in
Japanese Patients with Adenocarcinoma of the Lung
Hidetaka Uramoto, PhD, MD, Tomoko So, PhD, MD, Yoshika Nagata, PhD, MD,
Koji Kuroda, PhD, MD, Yoshiki Shigematsu, PhD, MD, Tetsuro Baba, PhD, MD,
Tetsuya So, PhD, MD, Mitsuhiro Takenoyama, PhD, MD, Takeshi Hanagiri, PhD, MD,
and Kosei Yasumoto, PhD, MD
Introduction: The identification of activating mutations in the
epidermal growth factor receptor (EGFR) gene is one of the most
intriguing recent discoveries in the field of lung cancer research, and
they are more commonly found in adenocarcinoma occurring in
females, never/light smokers, and East Asian patients. Why such
certain patients are susceptible to the development of EGFR-mutant
tumors is currently unknown.
Methods: This study evaluated the medical records of 437 patients
with adenocarcinoma of the lung who underwent a surgical resec-
tion. The genetic status of the EGFR gene was investigated by
polymerase chain reaction-based analyses. The serological typing of
histocompatibility leukocyte antigen (HLA) class I was performed
using a microcytotoxicity test of lymphocytes or polymerase chain
reaction-sequence-specific oligonucleotides, and the correlation be-
tween the EGFR mutation and HLA alleles was analyzed.
Results: An EGFR mutation was found more frequently in females
and never/former smokers than their counterpart. In females, the
incidences of EGFR mutation were 61.0% and 41.7% in HLA-A2
() and A2 () patients with adenocarcinoma of the lung, respec-
tively (p  0.008). The EGFR mutation was found more frequently
in female patients with HLA-A2. However, no significant correla-
tion was identified between the frequencies of other HLA alleles and
EGFR mutations in the same patients group.
Conclusions: EGFR mutations are associated with HLA-A2 in
female patients with adenocarcinoma of the lung. Further research
was needed to elucidate the other relevant factors in the histogenesis
of lung cancer with an EGFR mutation.
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Lung cancer is the most common cause of cancer death inthe majority of developed countries.1 The absolute number
of patients with lung cancer is still increasing worldwide.2
Despite advances in therapeutic modalities, the prognosis of
lung cancer is poor.3,4 In particular, the patients with ad-
vanced-stage disease experienced a high mortality rate de-
spite multidisciplinary treatment.4 Therefore, the develop-
ment of new modalities such as molecular target therapy is
needed. Recently, epidermal growth factor receptor (EGFR)-
tyrosine kinase inhibitor has shown dramatic clinical re-
sponse in a significant proportion of patients harboring an
EGFR mutation.5–8 Such EGFR mutations occur more fre-
quently in females, nonsmokers, Asians, and adenocarcinoma
than in their counterparts.9,10 However, there is no reliable
information concerning carcinogens or molecules that affect
the EGFR mutation in lung cancer susceptibility to make a
paradigm shift from a preventive point of view.
The major histocompatibility complex, namely, the histo-
compatibility leukocyte antigen (HLA) in humans, is specific to
each individual and has some hereditary features such as hap-
lotype inheritance, allele polymorphism, and linkage disequilib-
rium. HLA class I molecules play a key role in the immune
response by presenting endogenous antigens to CD8 positive T
cells. The natural killer cells also specifically recognize HLA
class I molecules, and this recognition inhibits the killing func-
tion of natural killer cells.11 The alleles of HLA are involved in
the immune response, and some particular HLA types influence
the susceptibility to several diseases, especially autoimmune
disease.12 HLA-A2 and -A24 are frequent in the Japanese
population, and several HLA alleles influence the prognosis of
lung cancer patients.13,14 Therefore, they may have many fea-
tures in common with the EGFR mutation among the Japanese.
These findings led to the speculation that the EGFR mutation
may occur in the tumor harboring a particular HLA type. This
study investigated the relationship between the EGFR mutation
and antigen frequencies of HLA-A and -B loci among patients
with adenocarcinoma of the lung.
PATIENTS AND METHODS
Patients
Patients provided written informed consent to partici-
pate in this study and to donate blood, and a signed consent
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form was also obtained from each patient before collection of
the blood samples. The institutional review board-approved
informed consent for the use of the tumor specimens was
obtained either from all the patients or from the patient’s legal
guardians. Tumor samples were obtained from 623 patients
with primary lung adenocarcinoma who had undergone a
surgical resection between April 1996 and February 2009.
Forty-seven patients were excluded from the analysis because
of insufficient blood samples (anemia or viral infections), and
the tumor samples from 139 patients were too small to extract
sufficient DNA for all the analyses that include the determi-
nation of the EGFR mutation. Finally, a total of 437 patients
(247 males and 190 females) were included in the analysis.
The patients ranged in age from 18 to 91 years (average age:
67.8 years). There were 167 never smokers, 109 former
smokers, and 161 current smokers. Former smokers were
defined as those who quit smoking at least 3 years before the
time of surgery. According to the international pathologic
staging system,15 the pathologic stages were diagnosed as
stage I in 283 patients (IA: 198, IB: 85), stage II in 45 (IIA:
10, IIB: 35), stage III in 91 (IIIA: 51, IIIB: 40), and stage IV
in 18. The patient characteristics are shown in Table 1.
The patients were followed up every month within the
first postoperative year and at approximately at 2- to 4-month
intervals thereafter. The evaluations included a physical ex-
amination, chest roentgenography, an analysis of blood
chemistry, and measurements of tumor markers. Chest and
abdominal computed tomography, brain magnetic resonance
imaging, and a bone scintiscan were performed every 6
months for 3 years after surgery. Additional examinations
were performed if any symptoms or signs of recurrence were
detected. The median follow-up periods were 47.4 months.
At the last follow-up, 257 patients were alive and free of
cancer, whereas 55 patients had died of other causes without
evidence of cancer, 63 patients were alive with recurrent
cancer, and 62 patients had died of cancer.
Detection of EGFR Mutations
Genomic DNA was extracted from each tumor. The
EGFR mutations were examined by previously described
methods.9 Briefly, the exon 19 deletion of EGFR was de-
tected by a simple screening method, which was the detection
of shorter band than 147 bp of the polymerase chain reaction
(PCR) product from wild-type allele on agarose gel electro-
phoresis. The exon 21 L858R point mutation was detected by
mutant-allele-specific amplification. The 3 ends of 22-bp
oligonucleotides changed as the PCR primers corresponded
to G for T of EGFR codon 858. Namely, the sense primer
sequence for wild type was 5-TCAAGATCACAGATTTT-
GGGCT and that for L858R mutation was 5-TCAAGAT-
CACAGATTTTGGGCG. The antisense primer sequence for
both wild type and mutant type was 5-CATCCTCCCCTG-
CATGTGTTAAAC. The PCR products were separated by
electrophoresis on a 2% agarose gel.
HLA Serological Typing
The serological typing for HLA class I antigens was
performed using a microcytotoxicity test of the lymphocytes16
from April 1996 to June 2003. From July 2003 to February
2009, HLA-A and -B loci, but not HLA-C locus, were examined
using PCR-sequence-specific oligonucleotides by SRS Inc., To-
kyo, Japan. Each examination was performed using fresh pe-
ripheral blood lymphocytes of patients. PCR-sequence-specific
oligonucleotides was developed as a new method with a high
specificity using a small amount of DNA. The 26 samples from
the lung cancer patients were checked using these two methods,
and all the results were completely consistent. HLA-B5 is a
broad antigen serotype that was divided into the heterogeneous
subgroups of HLA-B51 and -B52 in 2004.17 Therefore, the samples
expressing B5 were rearranged for B51 or B52 in this study.
Statistical Analysis
Statistical associations were determined by the 2 test.
The Kaplan-Meier method was used to estimate the probability
of survival, and survival differences were analyzed by the
log-rank test. The statistical difference was considered to be signif-
icant if the p value was less than 0.05. The data were analyzed with
the use of the Abacus Concepts; Survival Tools for the StatView
software package (Abacus Concepts, Inc., Berkeley, CA).
RESULTS
Relationship Between EGFR Mutation and
Clinicopathological Factors
EGFR mutations were detected in 165 patients (37.8%)
among 437 patients. Ninety-four (21.5%) patients exhibited
the L858R point mutation in exon 21 and 71 (16.2%) had an
inframe deletion in exon 19. An EGFR mutation was found
more frequently in females and never/former smokers than
their counterparts (Table 2). No significant correlation was
identified between the EGFR mutations and age, pathologic
stage, pathologic T status, and pathologic N status. Next, we
investigated the relationship between allele frequencies of
HLA and EGFR mutation to interpret the phenomenon show-
ing a high frequency of EGFR mutation in females and
never/former smokers.
TABLE 1. Characteristics of the Adenocarcinoma Patients
in This Study
Characteristics
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Relationship Between Allele Frequencies of
HLA-A and -B and EGFR Mutation
The allele frequencies of HLA-A and -B are summa-
rized in Table 3. HLA-A2 and HLA-A24 were found as
frequently as 41.9% and 65.0% in all the patients with
adenocarcinoma of the lung, respectively. Such frequencies
of HLA in adenocarcinoma of the lung were almost similar to
those in Japanese normal healthy persons.18 No significant
association was identified between the frequencies of HLA-A
and -B and EGFR mutations among all patients with adeno-
carcinoma (Table 3). The correlation between the frequencies
of HLA-A and -B and EGFR mutations were also analyzed
independently in female and males. In females, the incidences
of EGFR mutation were 61.0% and 41.7% in HLA-A2 ()
and A2 () patients with adenocarcinoma of the lung, re-
spectively (p  0.008). According to the correction of the p
value by Yates, the p value was changed from 0.008 to 0.013.
However, no significant correlation was identified between
the frequencies of other HLA alleles and EGFR mutations in
the same group of patients (Table 4). No significant correla-
tion was identified between the frequencies of HLA alleles
and EGFR mutations in male patients with adenocarcinoma
(Table 5). Among nonsmoker patients with adenocarcinoma
of the lung, no significant correlation was identified between
the frequencies of HLA alleles and EGFR mutations (Table
6). An analysis of smokers with adenocarcinoma also pro-
duced the negative correlation between EGFR mutation and
HLA allele (Table 7). To rule out any bias due to an unequal
distribution of the smoking status, the association between
HLA-A2 positive or HLA-A2 negative females with the
EGFR mutation status was investigated. However, no signif-
icant correlation was identified between the phenotype fre-
quencies of EGFR mutation and the smoking status. To avoid
any bias due to an unequal distribution of the smoking status,
no influence on the overall and progression-free survival in
comparison to the others. No significant correlation was
identified between the phenotype frequencies of HLA-A2 and
the smoking status (p  0.604). No significant correlation
was also identified between the EGFR mutations and
HLA-A2 homozygous/heterozygous in HLA-A2 positive fe-
male patients. We examined the survival analysis as stratified
by the HLA-A2 positive female patients with the EGFR
mutation. The 5-year survival of HLA-A2 positive and
HLA-A2 negative patients was 72.8% and 69.1%, respec-
tively. The expression status of HLA-A2 positive female
patients with the EGFR mutation had no significant influence
on the overall and progression-free survival in comparison
with the others.
DISCUSSION
EGFR mutations occur more frequently in the Japanese
than the Caucasian population.19 The frequencies of HLA-A2










Gender Male 247 70 (28.3) 177
Female 190 95 (50.0) 95 0.001
Age (yr) 70 216 86 (39.8) 130
70 221 79 (35.7) 142 0.380
Smoking Never/former 276 133 (48.2) 143
Current 161 32 (19.9) 129 0.001
Pathological
stage
I–II 328 121 (36.9) 207
III–IV 109 44 (40.4) 65 0.517
pT T1–2 379 144 (38.0) 235
T3–4 58 21 (36.2) 37 0.794
pN Negative 312 120 (38.5) 192
Positive 125 45 (36.0) 80 0.632
EGFR, epidermal growth factor receptor; Mut, mutation of EGFR; Wt, wild type of
EGFR; pT, Pathological T status; pN, pathological N status.
TABLE 3. Relationships Between EGFR Mutation and HLA









A2  183 41.9 75 (41.0) 108
 254 90 (35.4) 164 0.238
A11  70 16.0 30 (42.9) 40
 367 135 (36.8) 232 0.337
A24  284 65.0 108 (38.0) 176
 153 57 (37.3) 96 0.874
A26  103 23.6 36 (35.0) 67
 334 129 (38.6) 205 0.502
A31  71 16.2 26 (36.6) 45
 366 139 (38.0) 227 0.829
A33  46 10.5 17 (37.0) 29
 391 148 (37.9) 243 0.906
B7  46 10.5 16 (34.8) 30
 391 149 (38.1) 242 0.660
B35  64 14.6 22 (34.4) 42
 373 143 (38.3) 230 0.546
B44  49 11.2 18 (36.8) 31
 388 147 (37.9) 241 0.876
B46  43 9.8 17 (39.5) 26
 394 148 (37.6) 246 0.800
B51  60 13.7 22 (36.7) 38
 377 143 (37.9) 234 0.851
B52  128 29.3 44 (34.4) 84
 309 121 (39.2) 188 0.348
B54  86 19.7 37 (43.0) 49
 351 128 (36.5) 223 0.261
B60  45 10.3 16 (35.6) 29
 392 149 (38.0) 243 0.747
B61  79 18.1 29 (36.7) 50
 358 136 (38.0) 222 0.831
B62  79 18.1 33 (41.8) 46
 358 132 (36.9) 226 0.416
EGFR, epidermal growth factor receptor; HLA, human leukocyte antigen; Mut,
mutation of EGFR; Wt, wild type of EGFR.
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expression in Caucasian and Japanese population have been
reported as 49.6% and 22.2 to 36.0%, respectively.18,20 On
the other hand, average phenotype frequency of HLA-A24
has been reported in Caucasian and Japanese population as
6.8% and 38.0%, respectively.18,21 These findings led to the
speculation that EGFR mutations may occur in tumors har-
boring particular HLA types. This study investigated the
relationship between EGFR mutations and allele frequencies
of HLA-A and -B in patients with adenocarcinoma of the
lung. Information regarding the EGFR mutations and HLA
class I type was accumulated in 437 Japanese patients with
adenocarcinoma. An EGFR mutation was found more fre-
quently in females and never/former smokers than in their
counterparts. These results are consistent with previous re-
ports.7,22,23 The phenotype frequencies of HLA-A2 and -A24
were around 25% and 40% in the Japanese normal healthy
population and also in lung cancer patients, respectively.18
One particular allele or gene marker directly or indirectly
involves disease susceptibility.24 The presentation of endog-
enous antigenic peptides is mediated by the major histocom-
patibility complex class I molecules.25–30 At the same time,
tumor cells often reveal a loss or downregulation of HLA
class I molecules on their surface to escape from immune
surveillance.31
Previously described genetic alterations in lung cancer
are almost always more frequent in smokers than nonsmok-
ers. For example, mutations of the p5332,33 and K-ras34 are
more frequent in smokers. Interestingly, EGFR mutations are
never found in tumors with KRAS mutations, showing a
mutually exclusive relationship, in other words, an either type
of mutation alone is thought to be sufficient for carcinogen-
esis of lung adenocarcinoma. In contrast, EGFR mutations
TABLE 4. Relationships Between EGFR Mutation and HLA










A2  82 50 (61.0) 32
 108 45 (41.7) 63 0.008
A11  31 18 (58.1) 13
 159 77 (48.4) 82 0.326
A24  127 61 (48.0) 66
 63 34 (54.0) 29 0.441
A26  44 21 (47.7) 23
 146 74 (50.7) 72 0.731
A31  29 12 (41.4) 17
 161 83 (51.6) 78 0.313
A33  20 8 (40.0) 12
 170 87 (51.2) 83 0.344
B7  13 6 (46.2) 7
 177 89 (50.3) 89 0.774
B35  30 14 (46.7) 16
 160 81 (50.6) 79 0.691
B44  21 9 (42.9) 12
 169 86 (50.9) 83 0.488
B46  23 12 (52.2) 11
 167 83 (49.7) 84 0.824
B51  26 15 (57.7) 11
 164 80 (48.8) 84 0.399
B52  56 24 (42.9) 32
 134 71 (53.0) 63 0.203
B54  30 18 (60.0) 12
 160 77 (48.1) 83 0.233
B60  19 6 (31.6) 13
 171 89 (52.0) 82 0.091
B61  38 16 (42.1) 22
 152 79 (52.0) 73 0.277
B62  32 19 (59.4) 13
 158 76 (48.1) 82 0.245
EGFR, epidermal growth factor receptor; HLA, human leukocyte antigen; Mut,
mutation of EGFR; Wt, wild type of EGFR.
TABLE 5. Relationships Between EGFR Mutation and HLA










A2  101 25 (24.8) 76
 146 45 (30.8) 101 0.298
A11  39 12 (30.8) 27
 208 58 (27.9) 150 0.713
A24  157 47 (29.9) 110
 90 23 (25.6) 67 0.462
A26  59 15 (25.4) 44
 188 55 (29.3) 133 0.567
A31  42 14 (33.3) 28
 205 56 (27.3) 149 0.431
A33  26 9 (34.6) 17
 221 61 (27.6) 160 0.453
B7  33 10 (30.3) 23
 214 60 (28.0) 154 0.788
B35  34 8 (23.5) 26
 213 62 (29.1) 151 0.503
B44  28 9 (32.1) 19
 219 61 (27.9) 158 0.635
B46  20 5 (25.0) 15
 227 65 (28.6) 162 0.730
B51  34 7 (20.6) 27
 213 63 (29.6) 150 0.280
B52  72 20 (27.8) 52
 175 50 (28.6) 125 0.900
B54  56 19 (33.9) 37
 191 51 (26.7) 140 0.291
B60  26 10 (38.5) 16
 221 60 (27.1) 161 0.226
B61  41 13 (31.7) 28
 206 57 (27.7) 149 0.600
B62  47 14 (29.8) 33
 200 56 (28.0) 144 0.807
EGFR, epidermal growth factor receptor; HLA, human leukocyte antigen; Mut,
mutation of EGFR; Wt, wild type of EGFR.
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and p53 mutations seemed to occur independently.35,36 Based
on an epidemiological study, smoking was found to be a
significant risk factor for non-small cell lung cancer
(NSCLC) without EGFR mutation.37 In Taiwan, human pap-
illoma virus type38 or cooking oil fumes39 have been inves-
tigated as a cause of lung cancer occurring in nonsmoking
women. Thus, these observations may suggest some associ-
ation with the preferential occurrence of EGFR mutations in
nonsmoking women. Recently, Matsuo et al.40 reported that
soybean products demonstrated a protective association with
EGFR mutations but not with EGFR wild-type NSCLC in a
case-control study. In this study, we showed that the EGFR
mutation was found more frequently in HLA-A2 () only for
the female patients. Recently, we demonstrated an association
between estrogen receptor expression and EGFR mutation in
lung adenocarcinoma, namely, strong estrogen receptor beta
expression was more frequent in adenocarcinoma with EGFR
mutations.10 The expression status of HLA-A2 positive had
no influence on the overall and progression-free survival in
comparison with those observed in the HLA-A2 negative
populations. We previously reported HLA-A2 to be associ-
ated with an unfavorable prognosis in Japanese lung cancer
patients.13,14 This discrepancy might therefore be due to the
existence of different populations because this research fo-
cused only on adenocarcinoma and not on NSCLC.
From the viewpoint of molecular biologic research, a
novel mutation in the 3-untranslated region of EGFR, which
is a different site in a classic sensitive kinase domain of
EGFR,41 was identified in colon tumors with microsatellite
instability. Genetic susceptibility to DNA repair defects could
predispose certain individuals to the development of EGFR
mutant tumors.42 In fact, mice carrying in the BRCA1 muta-
tion that eliminates the C-terminal half of the protein product
TABLE 6. Relationships Between EGFR Mutation and HLA










A2  74 45 (60.8) 29
 93 48 (51.6) 45 0.235
A11  27 19 (70.4) 8
 140 74 (52.9) 66 0.094
A24  104 56 (53.8) 48
 63 37 (58.7) 26 0.538
A26  40 24 (60.0) 16
 127 69 (54.3) 58 0.529
A31  27 12 (44.4) 15
 140 81 (57.9) 59 0.199
A33  21 11 (52.4) 10
 146 82 (56.2) 64 0.744
B7  11 4 (36.4) 7
 156 89 (57.1) 67 0.218
B35  25 14 (56.0) 11
 142 79 (55.6) 63 0.973
B44  21 11 (52.4) 10
 146 82 (56.2) 64 0.744
B46  18 9 (50.0) 9
 149 84 (56.4) 65 0.607
B51  21 14 (66.7) 7
 146 79 (54.1) 67 0.279
B52  49 23 (46.9) 26
 118 70 (59.3) 48 0.142
B54  31 22 (71.0) 9
 136 71 (52.2) 65 0.058
B60  17 8 (47.1) 9
 150 85 (56.7) 65 0.450
B61  31 14 (45.2) 17
 136 79 (58.1) 57 0.191
B62  32 22 (68.8) 10
 135 71 (52.6) 64 0.100
EGFR, epidermal growth factor receptor; HLA, human leukocyte antigen; Mut,
mutation of EGFR; Wt, wild type of EGFR.
TABLE 7. Relationships Between EGFR Mutation and HLA









A2  109 30 (27.5) 79
 161 42 (26.1) 119 0.794
A11  43 11 (25.6) 32
 227 61 (26.9) 166 0.861
A24  180 52 (28.9) 128
 90 20 (22.2) 70 0.243
A26  63 12 (19.0) 51
 207 60 (29.0) 147 0.118
A31  44 14 (31.8) 30
 226 58 (25.7) 168 0.398
A33  25 6 (24.0) 19
 245 66 (26.9) 179 0.752
B7  35 12 (34.3) 23
 235 60 (25.5) 175 0.275
B35  39 8 (20.5) 31
 231 64 (27.7) 167 0.347
B44  28 7 (25.0) 21
 242 65 (26.9) 177 0.833
B46  25 8 (32.0) 17
 245 64 (26.1) 181 0.527
B51  39 8 (20.5) 31
 231 64 (27.7) 167 0.347
B52  79 21 (26.6) 58
 191 51 (26.7) 140 0.984
B54  55 15 (27.3) 40
 215 57 (26.5) 158 0.909
B60  28 8 (28.6) 20
 242 64 (26.4) 178 0.810
B61  48 15 (31.3) 33
 222 57 (25.7) 165 0.428
B62  47 11 (23.4) 36
 223 61 (27.4) 162 0.578
EGFR, epidermal growth factor receptor; HLA, human leukocyte antigen; Mut,
mutation of EGFR; Wt, wild type of EGFR.
Uramoto et al. Journal of Thoracic Oncology • Volume 5, Number 8, August 2010
Copyright © 2010 by the International Association for the Study of Lung Cancer1140
develop bronchioloalveolar lung tumors.43 The mutation in
the 3-untranslated region of EGFR, through an enhanced
EGFR mRNA stability, has thus been shown to result in an
overexpression of EGFR.44 The expression of EGFR is often
associated with either polysomy or the amplification of
EGFR.45 Associations between activating mutation and copy
gain were also observed for EGFR in NSCLC.46 Sueoka-
Aragane et al.36 reported that EGFR mutations are closely
associated with a shorter cytosine-adenine repeat length in the
shorter allele. Therefore, an interaction clearly exists between
the length of a polymorphism in intron 1 of EGFR as an
inherited genetic factor and the frequency of EGFR amplifi-
cations as an acquired genetic factor, whereas both factors
contribute to the overexpression of EGFR in breast cancer.47
However, there is no direct data between EGFR mutation and
carcinogen or molecule to affect the EGFR mutation suscep-
tibility in adenocarcinoma patients to the present. Whether
the HLA alleles have any relationship to the EGFR mutation
is a subject for speculation and for study. A significant
correlation was identified between the phenotype frequencies
of HLA-A2 () alleles and EGFR mutation in female pa-
tients with adenocarcinoma of the lung. The EGFR is located
on chromosome 7p11.2 and EGFR overexpression is fre-
quently observed in NSCLC, and it correlates with an in-
creased gene copy number.45 On the other hand, HLA class I
was mapped on chromosome 6p21.3. No direct relationship
was observed between the chromosome alteration of 7p and
6p in lung adenocarcinoma.48 Recently, Wei et al.49 reported
the chromosomal abnormalities of EGFR to be often accom-
panied by chromosomal aneuploidy, as demonstrated in 6p.
However, the reason why no other HLA type, except for
HLA-A2, was indirectly linked to an EGFR mutation still
remains to be elucidated. Therefore, future research is ex-
pected to clarify the molecule that affects the EGFR mutation
in female patients with adenocarcinoma of the lung, which is
thus expected to lead to the development of new preventive
strategies.
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